KALARIS THERAPEUTICS INC (KLRS) Stock Price, Forecast & Analysis
USA - NASDAQ:KLRS - US4829291065 - Common Stock
KLRS Key Statistics, Chart & Performance
The current stock price of KLRS is 6.58 USD. In the past month the price increased by 50.23%.
KLRS Latest News, Press Relases and Analysis
KLRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.45 | 408.15B | ||
| AMGN | AMGEN INC | 15.57 | 183.27B | ||
| GILD | GILEAD SCIENCES INC | 15.48 | 157.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.19 | 107.65B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.64 | 74.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 905.49 | 60.53B | ||
| INSM | INSMED INC | N/A | 42.73B | ||
| NTRA | NATERA INC | N/A | 29.87B | ||
| BIIB | BIOGEN INC | 9.97 | 24.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 21.55B | ||
| INCY | INCYTE CORP | 15.84 | 19.86B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.3 | 13.80B |
Related stock screener links
About KLRS
Company Profile
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 6 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Company Info
KALARIS THERAPEUTICS INC
628 Middlefield Road
Palo Alto CALIFORNIA US
Employees: 6
Phone: 16502492727
KALARIS THERAPEUTICS INC / KLRS FAQ
What does KALARIS THERAPEUTICS INC do?
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 6 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Can you provide the latest stock price for KALARIS THERAPEUTICS INC?
The current stock price of KLRS is 6.58 USD. The price increased by 2.02% in the last trading session.
Does KLRS stock pay dividends?
KLRS does not pay a dividend.
What is the ChartMill technical and fundamental rating of KLRS stock?
KLRS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
When does KALARIS THERAPEUTICS INC (KLRS) report earnings?
KALARIS THERAPEUTICS INC (KLRS) will report earnings on 2026-03-05, after the market close.
Who owns KALARIS THERAPEUTICS INC?
You can find the ownership structure of KALARIS THERAPEUTICS INC (KLRS) on the Ownership tab.
Can you provide the short interest for KLRS stock?
The outstanding short interest for KALARIS THERAPEUTICS INC (KLRS) is 2.51% of its float.
KLRS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to KLRS.
KLRS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KLRS. KLRS has a great financial health rating, but its profitability evaluates not so good.
KLRS Financial Highlights
Over the last trailing twelve months KLRS reported a non-GAAP Earnings per Share(EPS) of -38.41. The EPS increased by 25.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.33% | ||
| ROE | -82.73% | ||
| Debt/Equity | 0 |
KLRS Forecast & Estimates
10 analysts have analysed KLRS and the average price target is 17.34 USD. This implies a price increase of 163.53% is expected in the next year compared to the current price of 6.58.